About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Insights - Voyageur Pharmaceuticals Ltd. has signed a collaboration and funding agreement with Bayer, providing milestone-based funding support of up to USD 2.35 million to develop iodine for medical imaging contrast media [1][2][3] Company Developments - The agreement includes an initial payment of USD 350,000 upon execution, USD 1,000,000 upon commencement of a feasibility study for an iodine extraction plant in Oklahoma, and another USD 1,000,000 upon completion of the study [3] - Voyageur has acquired iodine intellectual property from Dr. Brian Mueller, positioning the company to be a key player in the global iodine supply chain [1] - The company aims to become the first domestic producer of iodine contrast media in the United States, enhancing the security of the North American healthcare supply chain [4][7] Project Details - Voyageur is working on feasibility studies for both the Bayer project and its own radiology drug production project, which includes producing barium contrast drugs from its Frances Creek project in British Columbia and iodine contrast media from the Anadarko basin in the USA [5][6] - Initial lab bench testing for the Bayer project has been completed, and the company plans to build a small transportable field unit to gather data for the feasibility study [6] Market Context - The global contrast media market was valued at USD 6.77 billion in 2024 and is projected to reach USD 13.86 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033 [8] - North America accounts for approximately 39.07% of the global iodine contrast media market, valued at USD 2.65 billion annually due to high imaging volumes [8] Strategic Vision - Voyageur aims to vertically integrate the barium and iodine contrast markets, controlling all primary input costs from sourcing raw materials to final production [10][13] - The company plans to transition into a high-margin domestic manufacturer of radiology drugs, ensuring product validation by regulatory agencies worldwide [11]

Company Overview - Proactive is a financial news and online broadcast organization that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates across key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Content Production - Proactive's editorial team produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - The content covers a wide range of topics, including medium and small-cap markets, blue-chip companies, commodities, biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows, utilizing both human expertise and technological tools [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Core Insights - Gossamer Bio's experimental drug for a serious lung and heart condition failed to meet the primary endpoint in a late-stage clinical trial [1] Company Summary - Gossamer Bio announced the failure of its experimental drug in a late-stage study, which is a significant setback for the company [1]

Core Insights - The European Commission has approved subcutaneous (SC) amivantamab, allowing for administration in minutes rather than hours, with efficacy and safety consistent with intravenous (IV) amivantamab [1][2][3] - SC amivantamab is now authorized for all previously approved IV indications, including every-four-week (Q4W) and every-three-week (Q3W) dosing regimens for advanced non-small cell lung cancer (NSCLC) [1][2][3][4] - The new dosing options aim to reduce administration-related reactions and improve patient convenience [1][2][3][4] Company Developments - Johnson & Johnson announced the approval of SC amivantamab, which is expected to enhance the treatment experience for patients with EGFR-mutated NSCLC [1][2][3] - The approval is part of Johnson & Johnson's commitment to improving patient care and treatment flexibility [1][2][3] Clinical Study Results - The approval is supported by Phase 2 PALOMA-2 and Phase 1 PALOMA studies, which demonstrated that SC amivantamab has a response rate and safety profile similar to IV amivantamab, but with significantly fewer administration-related reactions [1][2][3][4] - Administration time for SC amivantamab is approximately five minutes, compared to five hours for the first IV infusion [1][2][3][4] Treatment Context - Amivantamab is a bispecific antibody targeting EGFR and MET mutations, which are prevalent in NSCLC [3][4] - The approval of SC amivantamab aligns with the growing need for more efficient treatment options in the context of lung cancer, which is the leading cause of cancer-related deaths in Europe [6][7]

Core Insights - Dividend stocks and Consumer Staples experienced losses or flat prices last week, with Crown Castle and AbbVie among the biggest decliners, while Coca-Cola outperformed due to positive Wall Street research notes [1] Group 1: Company Performance - Crown Castle (CCI) saw a significant decline after terminating its agreement with DISH Wireless due to a default on payment obligations, leading to a potential $3.5 billion revenue shortfall and an expected net loss of $780 million in 2026 [1] - AbbVie (ABBV) dropped nearly 3% despite FDA approvals for its drug, facing headwinds from broader healthcare sector weakness and drug pricing policy uncertainties [1] - AT&T (T) fell approximately 2.5% after two banks lowered their price targets, reflecting concerns about the competitive telecom environment, particularly with T-Mobile's new service [1] Group 2: Dividend Changes - Crown Castle reduced its quarterly dividend from $1.565 to $1.0625 per share, raising questions about the sustainability of its dividend amid financial challenges [1] - AbbVie has increased its dividend for 13 consecutive years, with the latest quarterly dividend at $1.73 per share, reflecting a 5.5% increase from the previous rate [1] - AT&T maintains a quarterly dividend of $0.2775 per share, yielding close to 4% at current prices, but faces limited near-term upside according to analyst consensus [1] Group 3: Market Trends - The Schwab U.S. Dividend Equity ETF was flat, while the Consumer Staples SPDR fell by 1.8%, indicating a pause in the performance of dividend stocks [1] - The VIX index is at 20.23, indicating a boundary between normal and elevated uncertainty, while the 10-year Treasury yield is at 4.08%, down from 4.29%, providing some relief for rate-sensitive dividend stocks [2] - Overall, 2026 has been a strong year for dividend stocks, with investors seeking stability amid market volatility [2]

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025. Webcast InformationDate: Monday, March ...

DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized. D ...

Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer, as part of the multi-year agreement between the companies. The installation was completed in January 2026.TRANSACTION HIGHLIGHTSThe present SDL ...

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University fo ...